Literature DB >> 12513961

Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned.

Richard J Bleicher1, David P Allegra, Dean T Nora, Thomas F Wood, Leland J Foshag, Anton J Bilchik.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is a promising technique for unresectable hepatic malignancies. We reviewed our RFA experience to identify variables affecting local recurrence.
METHODS: Patients undergoing RFA between 1997 and 2001 were reviewed for demographics, tumor size, pathology, diagnosis, recurrence, procedures, survival, and complications.
RESULTS: The 447 unresectable liver tumors were ablated in 198 procedures. The 153 patients averaged 61.9 years of age and 1.25 RFA procedures per patient. Follow-up averaged 11 months. Serial ablations were performed in 28 patients, 8 of whom are without evidence of disease. Tumors were most commonly carcinomas of colorectal, hepatocellular, breast, and melanoma histologies. Colorectal carcinomas and hepatomas individually recurred more frequently than all other tumor types combined in univariate analyses (P =.009 and P =.008, respectively). Patients with multiple tumors ablated recurred significantly more frequently (P =.001). Size was also significant in univariate and multivariate analyses (P =.0032 and <.0001, respectively). Eighteen patients experienced 36 complications.
CONCLUSIONS: Size has the highest correlation with local recurrence, but multiple tumors and pathology may also predict local recurrence risk. Large, complex lesions can be safely serially ablated, but because of morbidity and recurrence, RFA should not replace resection as the primary treatment of resectable liver tumors.

Entities:  

Mesh:

Year:  2003        PMID: 12513961     DOI: 10.1245/aso.2003.03.018

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  55 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

2.  Radiofrequency ablation in a previously irradiated liver.

Authors:  Marc A Friedman; Rosemary Altemus; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2003-10       Impact factor: 3.464

3.  Pringle maneuver deteriorates gut barrier dysfunction induced by extended-liver radiofrequency ablation.

Authors:  Petros Ypsilantis; Maria Lambropoulou; Anastasia Grapsa; Ioannis Tentes; Christina Tsigalou; Maria Panopoulou; Constantinos Simopoulos
Journal:  Dig Dis Sci       Date:  2010-10-24       Impact factor: 3.199

Review 4.  Complications of intraoperative radiofrequency ablation of liver metastases.

Authors:  Tsiriniaina Razafindratsira; Milène Isambert; Serge Evrard
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

Review 5.  The Emprint™ Ablation System with Thermosphere™ Technology: One of the Newer Next-Generation Microwave Ablation Technologies.

Authors:  Marc Alonzo; Aaron Bos; Shelby Bennett; Hector Ferral
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

6.  [Liver tumor ablation].

Authors:  Th Helmberger; R-Th Hoffmann; T Jakobs; Th Leibecke; A Lubienski; M Reiser
Journal:  Radiologe       Date:  2005-01       Impact factor: 0.635

Review 7.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

8.  Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients.

Authors:  Timothy M Pawlik; Francesco Izzo; Deborah S Cohen; Jeffery S Morris; Steven A Curley
Journal:  Ann Surg Oncol       Date:  2003-11       Impact factor: 5.344

9.  Safety and outcomes following resection of colorectal liver metastases in the era of current perioperative chemotherapy.

Authors:  Ilia Gur; Brian S Diggs; Jesse A Wagner; Gina M Vaccaro; Charles D Lopez; Brett C Sheppard; Susan L Orloff; Kevin G Billingsley
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

Review 10.  Radiofrequency ablation of cancer.

Authors:  Marc Friedman; Igor Mikityansky; Anthony Kam; Steven K Libutti; McClellan M Walther; Ziv Neeman; Julia K Locklin; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2004-06-03       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.